4 RESULTS
COMMENT As most phosphorylated-tau biomarkers available in blood or CSF reflect mainly Aβ-related pathology, there is an urgent need for the identification of cost-effective and scalable fluid biomarkers specific for tau aggregate pathology in Alzheimer’s disease
COMMENT This report by Groot and colleagues takes the critical step in the current AT(N) framework to suggest further classification with “P”, phosphorylated tau (p-tau). In this study, the team deeply characterized CSF p-tau217 as a representative of this propos
COMMENT This is a very comprehensive proteomic study of more than 1,000 brain tissue samples using a tandem-mass-tag mass spectrometry approach. The point of this study is that the authors leveraged brain tissue proteomics with the data from other-omics modalitie
COMMENT There is an entire field of exploration to understand the nature of pathological tau species in AD amongst monomeric, oligomeric, and fibrillary and modified tau species. The study by Dujardin et al. provides new insight to posit that seed-competent tau s
